Still, the decreased cystine intake following sorafenib treatment observed in our experiments (Figure 2A) suggests that SLC7A11 inhibition due to increased BECN1 binding outweighs the effects of upregulated SLC7A11 expression in sorafenib-triggered HCC ferroptosis. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.